TY - JOUR
T1 - Oestradiol measurement during Fulvestrant treatment for breast cancer
AU - Owen, Laura
AU - Monaghan, Philip
AU - Armstrong, Anne
AU - Keevil, Brian
AU - Higham, Claire
AU - Salih, Zenah
AU - Howell, Sacha
N1 - Publisher Copyright:
© 2019, Cancer Research UK.
PY - 2019/2/19
Y1 - 2019/2/19
N2 - Biochemical evaluation of menopausal status is used to inform treatment decisions, including clinical trial eligibility in women with oestrogen receptor positive breast cancer. However, fulvestrant may interfere with oestradiol immunoassays and confound accurate assessment in this context. We conducted a service evaluation of two immunoassays and an LC-MS/MS assay to determine the extent of the interference. Serum oestradiol levels were analysed by two immunoassays (Siemens Centaur XP and Abbott Architect) and liquid chromatography-tandem mass spectrometry (LC/MS/MS). Immunoassay gave higher serum oestradiol results than LC-MS/MS at low concentrations, with improved analytical sensitivity demonstrated by LC-MS/MS. Cross-reactivity of fulvestrant was observed for each immunoassay. We have shown that two commonly used immunoassays do not demonstrate the required sensitivity or specificity for the measurement of oestradiol in a breast cancer population. For patients receiving fulvestrant, spurious results may be generated that could impact treatment decisions. LC-MS/MS is recommended in this setting.
AB - Biochemical evaluation of menopausal status is used to inform treatment decisions, including clinical trial eligibility in women with oestrogen receptor positive breast cancer. However, fulvestrant may interfere with oestradiol immunoassays and confound accurate assessment in this context. We conducted a service evaluation of two immunoassays and an LC-MS/MS assay to determine the extent of the interference. Serum oestradiol levels were analysed by two immunoassays (Siemens Centaur XP and Abbott Architect) and liquid chromatography-tandem mass spectrometry (LC/MS/MS). Immunoassay gave higher serum oestradiol results than LC-MS/MS at low concentrations, with improved analytical sensitivity demonstrated by LC-MS/MS. Cross-reactivity of fulvestrant was observed for each immunoassay. We have shown that two commonly used immunoassays do not demonstrate the required sensitivity or specificity for the measurement of oestradiol in a breast cancer population. For patients receiving fulvestrant, spurious results may be generated that could impact treatment decisions. LC-MS/MS is recommended in this setting.
UR - http://www.scopus.com/inward/record.url?scp=85060688857&partnerID=8YFLogxK
UR - http://www.mendeley.com/research/oestradiol-measurement-during-fulvestrant-treatment-breast-cancer
U2 - 10.1038/s41416-019-0378-9
DO - 10.1038/s41416-019-0378-9
M3 - Article
SN - 0007-0920
VL - 120
SP - 404
EP - 406
JO - British Journal of Cancer.
JF - British Journal of Cancer.
IS - 4
ER -
